Che_2024_Arch.Dermatol.Res_316_301

Reference

Title : Lipid traits and lipid-lowering drug target genes and risk of melanoma: a mendelian randomization study - Che_2024_Arch.Dermatol.Res_316_301
Author(s) : Che Y , Yuan J , Tang D , Guo J
Ref : Arch Dermatol Res , 316 :301 , 2024
Abstract :

Our study aimed to investigate the role of lipids in melanoma risk and the effect of lipid-lowering drug targets on melanoma. Using Mendelian Randomization analysis, we examined the genetic agents of nine lipid-lowering drugs and their association with melanoma risk. We found that genetically proxied inhibition of HMGCR, ABCG5/ABCG8, and ANGPTL3 was associated with a reduced risk of melanoma. On the other hand, inhibition of LPL and Apo-B100 was significantly associated with an increased risk of melanoma. Sensitivity analyses did not reveal any statistical evidence of bias from pleiotropy or genetic confounding. We did not find a robust association between lipid traits NPC1L1, PCSK9, APOC3 inhibition, and melanoma risk. These findings were validated using two independent lipid datasets. Our analysis also revealed that HMGCR, ANGPTL3, and ABCG5/ABCG8 inhibitors reduced melanoma risk independent of their effects on lipids. This suggests that these targets may have potential for melanoma prevention or treatment. In conclusion, our study provides evidence for a causal role of lipids in melanoma risk and highlights specific lipid-lowering drug targets that may be effective in reducing the risk of melanoma. These findings contribute to the understanding of the underlying mechanisms of melanoma development and provide potential avenues for further research and therapeutic interventions.

PubMedSearch : Che_2024_Arch.Dermatol.Res_316_301
PubMedID: 38819656

Related information

Citations formats

Che Y, Yuan J, Tang D, Guo J (2024)
Lipid traits and lipid-lowering drug target genes and risk of melanoma: a mendelian randomization study
Arch Dermatol Res 316 :301

Che Y, Yuan J, Tang D, Guo J (2024)
Arch Dermatol Res 316 :301